Wells Fargo’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-270
| Closed | -$1.71K | – | 7856 |
|
|
2022
Q4 | $1.71K | Buy |
270
+138
| +105% | +$764 | ﹤0.01% | 6047 |
|
|
2022
Q3 | $1K | Sell |
132
-214,587
| -100% | -$1.35M | ﹤0.01% | 6553 |
|
|
2022
Q2 | $1.34M | Buy |
214,719
+214,602
| +183,421% | +$723K | ﹤0.01% | 3090 |
|
|
2022
Q1 | $0 | Buy |
117
+1
| +0.9% | +$4 | ﹤0.01% | 8191 |
|
|
2021
Q4 | $1K | Buy |
116
+7
| +6% | +$42 | ﹤0.01% | 7128 |
|
|
2021
Q3 | $1K | Sell |
109
-6
| -5% | -$41 | ﹤0.01% | 6869 |
|
|
2021
Q2 | $1K | Buy |
115
+61
| +113% | +$520 | ﹤0.01% | 6801 |
|
|
2021
Q1 | $1K | Buy |
54
+30
| +125% | +$291 | ﹤0.01% | 6806 |
|
|
2020
Q4 | $0 | Hold |
24
| – | – | ﹤0.01% | 7266 |
|
|
2020
Q3 | $0 | Buy |
24
+4
| +20% | +$24 | ﹤0.01% | 7152 |
|
|
2020
Q2 | $0 | Buy |
20
+1
| +5% | +$6 | ﹤0.01% | 7045 |
|
|
2020
Q1 | $0 | Sell |
19
-1,099
| -98% | -$5.69K | ﹤0.01% | 7048 |
|
|
2019
Q4 | $7K | Sell |
1,118
-3,696
| -77% | -$47K | ﹤0.01% | 5988 |
|
|
2019
Q3 | $67K | Buy |
4,814
+814
| +20% | +$13.4K | ﹤0.01% | 5472 |
|
|
2019
Q2 | $59K | Sell |
4,000
-1,382
| -26% | -$37K | ﹤0.01% | 5494 |
|
|
2019
Q1 | $225K | Buy |
5,382
+371
| +7% | +$15.6K | ﹤0.01% | 4761 |
|
|
2018
Q4 | $208K | Buy |
5,011
+2,407
| +92% | +$108K | ﹤0.01% | 4875 |
|
|
2018
Q3 | $125K | Buy |
2,604
+219
| +9% | +$11K | ﹤0.01% | 5255 |
|
|
2018
Q2 | $114K | Buy |
2,385
+518
| +28% | +$28.7K | ﹤0.01% | 5317 |
|
|
2018
Q1 | $115K | Sell |
1,867
-10
| -0.5% | -$528 | ﹤0.01% | 5250 |
|
|
2017
Q4 | $101K | Buy |
+1,877
| New | +$112K | ﹤0.01% | 5308 |
|
Wells Fargo's FSTX Position: Q1 2023 in Review
Wells Fargo sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 270 shares — an estimated $1.71K sold.
Wells Fargo first reported a position in FSTX in Q4 2017 and held it in 21 quarters. The position peaked at $1.34M in Q2 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Wells Fargo reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Wells Fargo sold 270 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.71K.
- Wells Fargo first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2017 and held it in 21 quarters.
- Wells Fargo's F-star Therapeutics, Inc. Common Stock position peaked at $1.34M in Q2 2022.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.